KAKU 2014
NCT01294423
A randomised clinical trial investigating the effect of dapagliflozin versus placebo in

1 Treatments

<table>
<thead>
<tr>
<th>Studied treatment</th>
<th>Control treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Concomittant treatments

2 Patients

<table>
<thead>
<tr>
<th>Patients</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion criteria</td>
<td>-</td>
</tr>
<tr>
<td>Exclusion criteria</td>
<td>-</td>
</tr>
</tbody>
</table>

3 Methods

<table>
<thead>
<tr>
<th>Blinding</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Design</td>
<td>-</td>
</tr>
<tr>
<td>Centers</td>
<td>-</td>
</tr>
<tr>
<td>Geographical area</td>
<td>Japan</td>
</tr>
<tr>
<td>Sample size</td>
<td>-18 (-9 / -9)</td>
</tr>
<tr>
<td>ArretTrt1</td>
<td>-</td>
</tr>
<tr>
<td>ArretTrt0</td>
<td>-</td>
</tr>
<tr>
<td>PeriodInclusion</td>
<td>-</td>
</tr>
<tr>
<td>Hypothese</td>
<td>-</td>
</tr>
</tbody>
</table>

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
</table>

5 References
6 Comments